News
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
Summary by Denton News Editorial Desk By Castle Biosciences, Inc. , as published by Denton Record-Chronicle
· June 25, 2026
· 1 min read
Photo: Denton Record-Chronicle · view original
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram
Sources and story details Story provenance No corrections
Summary created by Denton News Editorial Desk — automated, rule-governed Byline on source page By Castle Biosciences, Inc., as published by Denton Record-Chronicle Original story Read at the source Source published Jun 25, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
More News Today’s briefing Local events
Frequently asked about this story
What is this story about? Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram
When was this published? This article was first published on June 25, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By Castle Biosciences, Inc. at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more News coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More News →
Today’s briefing
Subscribe to newsletter
